'%3e%3cpath%20d='M34.1406%205.85938C30.3906%202.10547%2025.3047%200%2020%200C14.6953%200%209.60938%202.10547%205.85938%205.85938C2.10938%209.61328%200%2014.6953%200%2020C0%2025.3047%202.10547%2030.3906%205.85938%2034.1406C9.61328%2037.8906%2014.6953%2040%2020%2040C25.3047%2040%2030.3906%2037.8945%2034.1406%2034.1406C37.8906%2030.3906%2040%2025.3047%2040%2020C40%2014.6953%2037.8945%209.60938%2034.1406%205.85938ZM37.0117%2023.543H31.1602V13.5391H27.6328V19.9414C28.1211%2020.6914%2028.3711%2021.582%2028.3711%2022.5625V22.625C28.3711%2023.668%2028.1172%2024.6055%2027.6328%2025.4297V26.6094H36.082C33.4883%2032.9375%2027.2891%2037.3789%2020.0039%2037.3789C10.3711%2037.3789%202.62109%2029.6289%202.62109%2020C2.62109%2010.3711%2010.3711%202.62109%2020%202.62109C29.6289%202.62109%2037.3789%2010.3711%2037.3789%2020C37.3789%2021.1484%2037.2617%2022.2656%2037.0508%2023.3477C37.0391%2023.4141%2037.0234%2023.4766%2037.0117%2023.543Z'%20fill='white'/%3e%3cpath%20d='M22.3086%2018.5352C20.4336%2018.125%2019.9531%2017.8398%2019.9766%2017.1836V17.1406C19.9766%2016.6992%2020.3477%2016.2148%2021.4023%2016.2148C22.582%2016.2148%2023.8867%2016.6797%2025.0781%2017.4766L26.8516%2015.0195C25.4453%2013.8906%2023.707%2013.3398%2021.5547%2013.3398C18.5195%2013.3398%2016.4375%2015%2016.4063%2017.4766V17.5352C16.3633%2020.2617%2018.5859%2020.9805%2021.293%2021.6016C23.0391%2021.9766%2023.5703%2022.3164%2023.5703%2022.9609L23.5469%2022.9766C23.5469%2023.3906%2023.2578%2023.7031%2022.7852%2023.8359C22.5742%2023.9062%2022.1289%2023.9727%2021.5156%2023.9727C20.7617%2023.9727%2019.7539%2023.8633%2018.6328%2023.4844C18.0898%2023.2891%2017.4727%2023.0039%2016.8047%2022.6133L20.1406%2026.625C20.2813%2026.6602%2021.0977%2026.8516%2021.7734%2026.8516C25.0039%2026.8516%2027.0859%2025.2461%2027.1094%2022.6328V22.5703C27.1602%2020.1133%2025.2148%2019.1719%2022.3086%2018.5352Z'%20fill='white'/%3e%3cpath%20d='M5.24219%2013.5664V26.6133H8.75391V23.7578L10.2969%2021.9531L14.2031%2026.6133H18.3867L12.3555%2019.5195L17.4023%2013.5664H13.4531L8.75391%2019.0586V13.5664H5.24219Z'%20fill='white'/%3e%3c/g%3e%3cdefs%3e%3cclipPath%20id='clip0_97_2430'%3e%3crect%20width='40'%20height='40'%20fill='white'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e)
Lifestyle Features
Most Recent
Lindsay Clancy trial highlights growing efforts to aid jurors after traumatic cases
Tom Hals, Reuters | Updated Sept. 4 - 2:02 p.m. | Save Story
For jurors in the six-week murder trial of Lindsay Clancy, the end of their service could be the start of the emotional fallout.
10 food deals to check out this Labor Day weekend
Caitlin Keith, Deseret News | Posted Sept. 4 - 1:17 p.m. | Save Story
As Americans prepare to celebrate Labor Day this weekend, a wide variety of fast-food and restaurant chains are offering special deals and discounts for the holiday.
Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose
Siddhi Mahatole and Christy Santhosh, Reuters | Updated Sept. 4 - 9:44 a.m. | Save Story
Ionis Pharmaceuticals said on Friday it would price its newly approved therapy to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the injectable drug, making it the first approved treatment for the genetic disorder in adults and children.
Cyclosporiasis cases in Michigan climb to over 14,700, state health officials say
Reuters | Updated Sept. 3 - 12:34 p.m. | Save Story
Michigan health officials reported 14,718 cases linked to an outbreak of cyclosporiasis on Thursday, an increase of 208 cases since its last update a week earlier.
Novartis MS pill beats older drug in trials, boosts pipeline hopes
Bhanvi Satija, Reuters | Updated Sept. 3 - 9:38 a.m. | Save Story
(Corrects paragraph 12 to say remi is approved to treat only one skin condition, not two)
AbbVie's blood cancer therapy lowers disease progression, death risk in trial
Puyaan Singh, Reuters | Updated Sept. 3 - 9:10 a.m. | Save Story
AbbVie said on Thursday its therapy for a type of blood cancer has improved patients' response rate to treatment and reduced the risk of disease progression or death, meeting the main goals of a late-stage trial.
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial
Kamal Choudhury, Reuters | Updated Sept. 3 - 7:53 a.m. | Save Story
Shares of Ultragenyx Pharmaceutical plunged on Thursday after its neurodevelopmental disorder treatment failed a closely watched late-stage trial, dealing a major blow to one of its biggest growth bets.
Aspen sees Mounjaro Africa sales above $124 million in 2027
Nqobile Dludla, Reuters | Posted Sept. 3 - 6:38 a.m. | Save Story
Aspen Pharmacare expects African sales of Eli Lilly's blockbuster weight-loss and diabetes drug Mounjaro to exceed 2 billion rand ($124 million) in its current financial year, buoyed by surging demand in South Africa and planned launches in Nigeria and Kenya.
Health officials turn to mobile-phone data to track Ebola spread in Congo
Clement Bonnerot, Reuters | Updated Sept. 3 - 5:26 a.m. | Save Story
Health officials battling the Ebola outbreak in eastern Democratic Republic of Congo are using anonymised mobile-phone data to map population movements and identify areas where the virus could spread next, according to the World Health Organisation and researchers working with it.
Transgene jumps 20% on positive cancer vaccine data in early trial
Reuters | Posted Sept. 3 - 2:22 a.m. | Save Story
Transgene shares surged 20% in early Paris trading on Thursday, after the French biotechnology company reported positive Phase 1 trial data on its vaccine candidate for head and neck cancer.
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
Reuters | Updated Sept. 3 - 1:50 a.m. | Save Story
GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker said on Thursday.
Nestle to build infant formula plant in Brazil as part of $393 million investment
Gabriel Araujo, Reuters | Posted Sept. 2 - 9:03 p.m. | Save Story
Nestle will invest 2 billion reais ($392.73 million) in its nutrition and health division in Brazil through 2028, including 600 million reais for a new infant formula factory in Minas Gerais state, the company said on Thursday.
Ultragenyx's rare disease drug fails in late-stage trial; shares plunge
Christy Santhosh, Reuters | Updated Sept. 2 - 4:14 p.m. | Save Story
Ultragenyx Pharmaceutical said on Wednesday its experimental drug for a rare genetic neurodevelopmental disorder did not meet the main goal in a late-stage trial, sending its shares down 45% in aftermarket trading.
Aspen bets on manufacturing rebound, obesity drug push for growth
Nqobile Dludla, Reuters | Updated Sept. 2 - 10:16 a.m. | Save Story
Aspen Pharmacare forecast strong double-digit earnings growth for fiscal 2027 on Wednesday, as the South African drugmaker bet on a sharp recovery in its manufacturing business and the global rollout of its generic weight-loss medicines.
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
Reuters | Updated Sept. 2 - 8:48 a.m. | Save Story
South Korea's Alteogen said on Wednesday it has signed a deal with Novartis worth up to $3.22 billion, giving the Swiss drugmaker access to its technology to make injectable versions of intravenous drugs.
Teva's immune disorder drug meets main goal in mid-stage trial
Reuters | Updated Sept. 2 - 8:48 a.m. | Save Story
Israeli drugmaker Teva Pharmaceutical Industries, said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of a mid-stage trial.
Owkin signs AI drug discovery deal with Boehringer for cancer, immunology
Sahil Pandey, Reuters | Updated Sept. 2 - 8:47 a.m. | Save Story
AI company Owkin said on Wednesday it has signed a licensing deal with Germany's Boehringer Ingelheim, giving the drugmaker access to its AI research platform and patient data to speed up discovery of drugs for cancer and immunity-related diseases.
Health Rounds: Scientists find genes linked to OCD, raising the prospect of new treatments
Nancy Lapid, Reuters | Updated Sept. 2 - 6:54 a.m. | Save Story
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays)
